<DOC>
	<DOCNO>NCT02871934</DOCNO>
	<brief_summary>This study determine whether use genetic test ( SLCO1B1 gene ) help patient provider choose right type dose cholesterol-lowering statin medication low risk cardiovascular disease , minimize muscle pain side effect sometimes occur statin .</brief_summary>
	<brief_title>Integrating Pharmacogenetics In Clinical Care</brief_title>
	<detailed_description>Variants rs4149056 SLCO1B1 gene associate great risk simvastatin-related myopathy . Despite grow implementation SLCO1B1 rs4149056 genotyping health system across United States , little randomize controlled trial data impact SLCO1B1 test clinical outcome . The IPICC Study use randomize design determine impact clinical integration SLCO1B1 genotype test important patient outcome , include statin prescribing , LDL cholesterol , statin-related myopathy . In addition , enrol statin-naive patient clinical moment provider order cholesterol panel , trial capture moment clinical decision-making SLCO1B1 rs4149056 genotype might clinically relevant . This randomized-control trial two primary aim : Aim 1 ( Drug safety ) : To determine impact SLCO1B1 pharmacogenetic test concordance Clinical Pharmacogenetics Implementation Consortium ( CPIC ) pharmacogenetic guideline safe simvastatin prescribe incidence statin-related myopathy VA ( drug safety ) . Aim 2 ( Cardiovascular disease , CVD , prevention ) : To determine impact SLCO1B1 pharmacogenetic test LDL cholesterol level concordance CVD prevention guideline . The IPICC Study enrol 400 statin-naive primary care woman 's health patient across Veteran Affairs Boston Healthcare System . Eligible patient age 45-70 elevate risk cardiovascular disease ( CVD ) accord American College Cardiology/American Heart Association ( ACC/AHA ) guideline . Primary care provider ( PCPs ) also research subject consent via electronic health record ( EHR ) alert . To model pharmacogenotyping point care , investigator enrol patient PCPs order cholesterol testing , indicate moment clinical decision-making CVD risk . Enrolled patient randomize PCPs receive result EHR immediately ( PGx+ ) vs. 1 year ( PGx- ) . The investigator query clinical pharmacy data 1-year outcome : myopathy concordance CPIC simvastatin guideline ( drug safety ) cholesterol level concordance ACC/AHA guideline ( CVD risk reduction ) .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Providers : All provider Primary Care Women 's Health VA Boston Healthcare System eligible participate . Patients : Aged 4075 year Have history statin use Have receive VA care least prior 6 month Are patient enrol provider Meet least 1 follow criterion : cardiovascular disease ( CVD ) diabetes LDL cholesterol value &gt; = 190 mg/dL 10year CVD risk 7.5 % , calculate ACC/AHA 2013 pool risk equation Patients ineligible : Do meet inclusion criterion Pregnant Incarcerated institutionalized</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pharmacogenetics</keyword>
	<keyword>SLCO1B1 protein , human</keyword>
	<keyword>OATP1B1 protein , human</keyword>
	<keyword>Simvastatin</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Statin-related myotoxicity</keyword>
	<keyword>Veterans</keyword>
	<keyword>Point-of-care</keyword>
</DOC>